Presence of CMV infection or disease is reduced using 3 months valganciclovir prophylaxis but still results in reduced BOS free and total survival in lung transplant recipientsBackgroundCytomegalovirus (CMV) is the most prevalent opportunistic infection after lung transplantation. CMV replication in the ...
9. Hirji, I., et al., Healthcare resource utilization of maribavir versus investigator-assigned therapy in transplant recipients with cytomegalovirus infection refractory (with or without genotypic resistance) to prior treatment...
2.Cho, S.Y., et al., Epidemiology, treatment patterns, and disease burden of cytomegalovirus in hematopoietic cell transplant recipients in selected countries outside of Europe and North America: A systematic review. Transpl Infect Dis, 2023. 25(...
CMV is a beta herpesvirus that commonly infects humans; serologic evidence of prior infection can be found in 40%-100% of various adult populations.14CMV typically resides latent and asymptomatic in the body but may reactivate during periods of immunosuppression. Serious disease may occu...
Infectious disease: Fusion toxin protein inhibits CMV infectionPREVENTION of communicable diseasesHUMAN cytomegalovirus diseasesGANCICLOVIRTHERAPEUTICSThe article presents information on use of fusion toxin protein based strategy for treatment of communicable diseases due to Human cytomegalovirus infections and to ...
You're more likely to get this infection if you have a weakimmune systemfromHIVorAIDS. CMV retinitis used to be very common among people with HIV before HIVdrugscame along in the 1990s. But thiseyedisease still affects a small number of people today. It's a leading cause of blindness in...
原文出处:European Commission (EC) Approves LIVTENCITY (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies...
Background Concurrent cytomegalovirus infection (CMVi) and gastrointestinal graft-versus-host disease (GI-GVHD) poses significant risks for increased morbidity and mortality in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Primary prophylaxis with letermovir therapy has been shown...
“PREVYMIS has been an important addition to the care of high-risk adult CMV-seropositive patients who have received allogeneic stem cell transplants to help prevent CMV infection and disease. We are delighted that PREVYMIS is now ...
19.Systematic Review and Meta-Analysis of Real-World Observational StudiesProvide Additional Evidence of Effectiveness of PREVYMIS TM in PreventingCytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT. EBMT-OS04-7 (2022). 20....